ArticleBiomedicines2023

Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients.

Andrea Lombardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.